AiCure

R&D Trends

Johnson & Johnson Innovation, University of Toronto collaborate

Wednesday, October 29, 2014 01:18 PM

Janssen has signed an agreement, facilitated by the Johnson & Johnson Innovation center in California, with the University of Toronto's Center for Collaborative Drug Research (CCDR) to form an open-source collaboration focused on novel therapeutic approaches to the treatment and management of mood disorders and Alzheimer's disease.

More... »


NIH launches Illuminating the Druggable Genome to find potential drug targets

Wednesday, October 29, 2014 01:09 PM

NIH has announced a new collaborative initiative to improve human health by exploring poorly understood genes that have the potential to be modified by medicines. The effort is part of an NIH Common Fund three-year pilot project called Illuminating the Druggable Genome (IDG). For the initial phase of the program, NIH has allocated $5.8 million to eight institutions and for intramural resources.

More... »

CenterWatch

Cancer Innovation forum calls for improving cancer research ecosystem

Monday, October 27, 2014 12:58 PM

Accelerating the delivery of promising new cancer treatments depends on one critical requirement—ensuring patients are actively involved in the cancer research and drug development process from beginning to end.

More... »

Five Prime Therapeutics expands respiratory collaboration with GSK

Monday, October 27, 2014 12:56 PM

Five Prime Therapeutics, based in South San Francisco, Calif., has expanded its respiratory disease research collaboration with GlaxoSmithKline established in 2012 to identify first-in-class agents and new mechanisms for the treatment of refractory asthma and chronic obstructive pulmonary disease.

More... »

France’s National Research Agency awards funding to OPTIVAC project

Monday, October 27, 2014 12:53 PM

Imaxio, a French biopharmaceutical company specialized in vaccines, has been awarded funding of $772,000 by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project “leveraging On t-cell immune resPonse To Improve influenza VACcines.”

More... »

Lilly, Zymeworks expand collaboration agreement

Friday, October 24, 2014 01:10 PM

Eli Lilly and Zymeworks, a Vancouver-based, privately held biotherapeutics company, are expanding an existing licensing and collaboration agreement. Originally announced in January, the global strategic collaboration is focused on the development of an undisclosed number of novel bi-specific antibody therapeutics using Zymeworks' proprietary Azymetric platform.

More... »

J&J Innovation adds J-Labs incubator at Texas Medical Center

Friday, October 24, 2014 01:07 PM

Johnson & Johnson Innovation plans to expand J-Labs (formerly Janssen Labs) to include a new incubator located within Texas Medical Center's new Innovation Institute. The 30,000-square-foot J-Labs facility will accommodate up to 50 life science startups.

More... »

European Union to boost Ebola research with $30.9 million

Thursday, October 23, 2014 01:17 PM

The European Commission (E.C.) has announced $30.9 million from the European Union (E.U.) budget for urgently needed Ebola research. The funding will go to five projects, ranging from a large-scale clinical trial of a potential vaccine, to testing existing and novel compounds to treat Ebola. The money from Horizon 2020, an E.U. research and innovation program, will be provided via a fast-track procedure in order to start work as soon as possible. The commission also is working with industry on the further development of vaccines, drugs and diagnostics for Ebola and other haemorrhagic diseases within the Innovative Medicines Initiative.

More... »

ALS ACT, ALS Association, Northeast ALS Consortium request proposals

Thursday, October 23, 2014 01:12 PM

ALS ACT, a novel academic-foundation-industry partnership; the ALS Association, a Wash. D.C.-based national nonprofit organization; and the translational Northeast ALS Consortium (NEALS) clinical trials network have announced a call for phase II clinical trial applications for novel, high-potential treatments in amyotrophic lateral sclerosis (ALS).

More... »

Profectus BioSciences receives Army funding for Ebola, Marburg viruses

Thursday, October 23, 2014 01:06 PM

Profectus BioSciences, a Baltimore, Md.-based clinical-stage vaccine company, and the Galveston National Laboratory (GNL) at the University of Texas Medical Branch at Galveston (UTMB) have received a three-year $8.5 million grant from the U.S. Army. The grant will support studies directed at early steps of the ongoing development of a vaccine to provide pre- and post-exposure protection against exposure with all major strains of Ebola and Marburg viruses.

More... »

Link to survey
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs